Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

664 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune Checkpoint Inhibition in Prostate Cancer.
Nicholson LT, Fong L. Nicholson LT, et al. Among authors: fong l. Trends Cancer. 2020 Mar;6(3):174-177. doi: 10.1016/j.trecan.2020.01.003. Epub 2020 Feb 6. Trends Cancer. 2020. PMID: 32101720
TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. de Kouchkovsky I, et al. Among authors: fong l. J Immunother Cancer. 2021 May;9(5):e002127. doi: 10.1136/jitc-2020-002127. J Immunother Cancer. 2021. PMID: 33980590 Free PMC article.
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
Simonds EF, Lu ED, Badillo O, Karimi S, Liu EV, Tamaki W, Rancan C, Downey KM, Stultz J, Sinha M, McHenry LK, Nasholm NM, Chuntova P, Sundström A, Genoud V, Shahani SA, Wang LD, Brown CE, Walker PR, Swartling FJ, Fong L, Okada H, Weiss WA, Hellström M. Simonds EF, et al. Among authors: fong l. J Immunother Cancer. 2021 Jun;9(6):e002181. doi: 10.1136/jitc-2020-002181. J Immunother Cancer. 2021. PMID: 34083417 Free PMC article.
On the Verge: Immunotherapy for Colorectal Carcinoma.
Oh DY, Venook AP, Fong L. Oh DY, et al. Among authors: fong l. J Natl Compr Canc Netw. 2015 Aug;13(8):970-8. doi: 10.6004/jnccn.2015.0117. J Natl Compr Canc Netw. 2015. PMID: 26285242 Review.
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. Zhao SG, et al. Among authors: fong l. J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141. J Natl Cancer Inst. 2019. PMID: 30321406
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, Sharma P, Fong L. Sinha M, et al. Among authors: fong l. J Immunother Cancer. 2021 May;9(5):e002254. doi: 10.1136/jitc-2020-002254. J Immunother Cancer. 2021. PMID: 33986125 Free PMC article. Clinical Trial.
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
Fong L, Morris MJ, Sartor O, Higano CS, Pagliaro L, Alva A, Appleman LJ, Tan W, Vaishampayan U, Porcu R, Tayama D, Kadel EE 3rd, Yuen KC, Datye A, Armstrong AJ, Petrylak DP. Fong L, et al. Clin Cancer Res. 2021 Sep 1;27(17):4746-4756. doi: 10.1158/1078-0432.CCR-21-0063. Epub 2021 Jun 9. Clin Cancer Res. 2021. PMID: 34108181 Free PMC article. Clinical Trial.
664 results